SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-20-001520
Filing Date
2020-02-03
Accepted
2020-02-03 17:29:01
Documents
13
Period of Report
2020-01-29
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm 8-K 27237
2 ex3-1.htm EX-3.1 9575
3 ex3-1_001.jpg GRAPHIC 146413
4 ex3-1_002.jpg GRAPHIC 140340
5 ex3-1_003.jpg GRAPHIC 147484
6 ex3-1_004.jpg GRAPHIC 199254
7 ex3-1_005.jpg GRAPHIC 193542
8 ex3-1_006.jpg GRAPHIC 175089
9 ex3-1_007.jpg GRAPHIC 210602
10 ex3-1_008.jpg GRAPHIC 194761
11 ex3-1_009.jpg GRAPHIC 57327
12 ex3-1_010.jpg GRAPHIC 89022
13 logo_001.jpg GRAPHIC 6869
  Complete submission text file 0001493152-20-001520.txt   2188697
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55453 | Film No.: 20569804
SIC: 2834 Pharmaceutical Preparations